Description: Tebanicline hydrochloride (also known as ABT-594, Ebanicline and ABT594 hydrochloride) is a novel, potent, orally bioavailable nAChR modulator with effective analgesic activity. It inhibits the binding of cytisine to α4β2 neuronal nAChRs with a Ki of 37 pM. Tebanicline is a potent synthetic nicotinic (non-opioid) analgesic drug developed by Abbott as a less toxic analogue of the potent poison dart frog-derived compound epibatidine, which is some 200x stronger than morphine as an analgesic but produces extremely dangerous toxic side effects. Like epibatidine, tebanicline showed potent analgesic activity against neuropathic pain in both animal and human trials, but with far less toxicity than its parent compound. It acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes.